Pdb33 Economic Evaluation of Three First-Line Medications in Painful Diabetic Peripheral Neurophaty in Mexico

Carlos, Fernando; Ramirez, Jhon F.; Galindo-Suarez, R.M.; Dueñas, Héctor

doi:10.1016/s1098-3015(10)72280-4

Cited by 2 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two studies, one of which was observational53 and one that was economic,54 provided data regarding compliance and costs associated with adherence to pain medications, respectively (Table 2). In the observational study,53 patients on OD propranolol for treating migraine demonstrated higher mean compliance rates (79.8%) than those on BID atenolol (60.0%).…”

Section: Resultsmentioning

confidence: 99%

“…An economic evaluation using a 3-month decision model of three first-line medications for diabetic peripheral neuropathic pain by Carlos et al54 comparing duloxetine OD, pregabalin BID, and gabapentin TID demonstrated that in comparison to TID and BID, OD dosing was associated with a comparative cost savings of US$98 and US$129 per patient, respectively (Table 4). Incremental cost per QALY gained with OD over TID was US$8821 (over the patients dosing lifetime).…”

Section: Resultsmentioning

confidence: 99%

“…Random-effect meta-analysis for the assessment of compliance on data from two studies indicated OD dosing was associated with a significantly greater compliance rate compared with >OD dosing (OR 2.24, 95% CI 1.38–3.66, P = 0.001, I 2 = 0.0%) (Table 3). 54,55 The remaining studies demonstrated that adherence rates varied with different assessment techniques; however, OD dosing had better adherence rates than BID/TID regimens 7,26,32…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis

Srivastava¹,

Arora²,

Kataria³

et al. 2013

PPA

View full text Add to dashboard Cite

ObjectivesTo assess the impact of reduced frequency of oral therapies from multiple-dosing schedules to a once-daily (OD) dosing schedule on adherence, compliance, persistence, and associated economic impact.MethodsA meta-analysis was performed based on relevant articles identified from a comprehensive literature review using MEDLINE® and Embase®. The review included studies assessing adherence with OD, twice-daily (BID), thrice-daily (TID), and four-times daily (QID) dosing schedules and costs associated with optimal/suboptimal adherence among patients with acute and chronic diseases. Effect estimates across studies were pooled and analyzed using the DerSimonian and Laird random-effect model.ResultsForty-three studies met inclusion criteria, and meta-analyzable data were available from 13 studies. The overall results indicated that OD schedules were associated with higher adherence rates (odds ratio [OR] 3.07, 95% confidence interval [CI] 1.80–5.23; P < 0.001 for OD versus > OD dosing) and compliance rates (OR 3.50, 95% CI 1.73–7.08; P < 0.001 for OD versus > OD dosing); persistence rates showed the same direction but were not statistically significant (OR 1.43, 95% CI 0.62–3.29; P = 0.405 for OD versus BID dosing). Results for each of the conditions were consistent with those observed overall with respect to showing the benefits of less frequent dosing. From a health economic perspective, higher adherence rates with OD relative to multiple dosing in a number of conditions were consistently associated with corresponding lower costs of health care resources utilization.ConclusionCurrent meta-analyses suggested that across acute and chronic disease states, reducing dosage frequency from multiple dosing to OD dosing may improve adherence to therapies among patients. Improving adherence may result in subsequent decreases in health care costs.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis

Srivastava¹,

Arora²,

Kataria³

et al. 2013

PPA

View full text Add to dashboard Cite

show abstract

“…Of the 255 abstracts, based on the inclusion criteria, 56 were selected for further review in full text. In the past 11 years, 55 publications examined economic outcomes associated with pregabalin in FM or neuropathic pain . These 55 publications presented results from 53 studies.…”

Section: Resultsmentioning

confidence: 99%

“…Twenty‐one economic evaluations were found for pregabalin in FM and neuropathic pain . The cost‐effectiveness of pregabalin was assessed with cost‐utility, cost‐effectiveness, and cost‐consequence analyses, most often in the US and Western European countries, but also in Canada, Brazil, Colombia, and Mexico (Table S2).…”

Section: Resultsmentioning

confidence: 99%